OHOlga Hartwig

Olga Hartwig

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Olga Hartwig has a total of 73 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Intestinal stroma guides monocyte differentiation to macrophages through GM-CSF

    by Egle Kvedaraite, Magda Lourda, Natalia Mouratidou, Tim Düking, Avinash Padhi, Kirsten Moll, Paulo Czarnewski, Indranil Sinha, Ioanna Xagoraris, Efthymia Kokkinou, et al.

    Stromal cells support epithelial cell and immune cell homeostasis and play an important role in inflammatory bowel disease (IBD) pathogenesis. Here, we quantify the stromal response to inflammation in pediatric IBD and reveal subset-specific inflammatory responses across colon segments and intestinal layers. Using data from a murine dynamic gut injury model and human ex vivo transcriptomic, protein and spatial analyses, we report that PDGFRA+CD142−/low fibroblasts and monocytes/macrophages co-localize in the intestine. In primary human fibroblast-monocyte co-cultures, intestinal PDGFRA+CD142−/low fibroblasts foster monocyte transition to CCR2+CD206+ macrophages through granulocyte-macrophage colony-stimulating factor (GM-CSF). Monocyte-derived CCR2+CD206+ cells from co-cultures have a phenotype similar to intestinal CCR2+CD206+ macrophages from newly diagnosed pediatric IBD patients, with high levels of PD-L1 and low levels of GM-CSF receptor. The study describes subset-specific changes in stromal responses to inflammation and suggests that the intestinal stroma guides intestinal macrophage differentiation.


  • Open Access

    Cell‐Derived Vesicles for Antibiotic Delivery—Understanding the Challenges of a Biogenic Carrier System

    by Eilien Heinrich, Olga Hartwig, Christine Walt, Arefeh Kardani, Marcus Koch, Leila Pourtalebi Jahromi, Jessica Hoppstädter, Alexandra K. Kiemer, Brigitta Loretz, Claus‐Michael Lehr, et al.

    Recently, extracellular vesicles (EVs) sparked substantial therapeutic interest, particularly due to their ability to mediate targeted transport between tissues and cells. Yet, EVs’ technological translation as therapeutics strongly depends on better biocompatibility assessments in more complex models and elementary in vitro–in vivo correlation, and comparison of mammalian versus bacterial vesicles. With this in mind, two new types of EVs derived from human B‐lymphoid cells with low immunogenicity and from non‐pathogenic myxobacteria SBSr073 are introduced here. A large‐scale isolation protocol to reduce plastic waste and cultivation space toward sustainable EV research is established. The biocompatibility of mammalian and bacterial EVs is comprehensively evaluated using cytokine release and endotoxin assays in vitro, and an in vivo zebrafish larvae model is applied. A complex three‐dimensional human cell culture model is used to understand the spatial distribution of vesicles in epithelial and immune cells and again used zebrafish larvae to study the biodistribution in vivo. Finally, vesicles are successfully loaded with the fluoroquinolone ciprofloxacin (CPX) and showed lower toxicity in zebrafish larvae than free CPX. The loaded vesicles are then tested effectively on enteropathogenic Shigella, whose infections are currently showing increasing resistance against available antibiotics.


  • Proteoid biodynamers for safe mRNA transfection via pH-responsive nanorods enabling endosomal escape

    by Sangeun Lee, Sarah Nasr, Sari Rasheed, Yun Liu, Olga Hartwig, Cansu Kaya, Annette Boese, Marcus Koch, Jennifer Herrmann, Rolf Müller, et al.


  • Open Access

    Regulatory modules mediating the complex neural expression patterns of the homeobrain gene during Drosophila brain development

    by Kirsten Hildebrandt, Dieter Kolb, Christine Klöppel, Petra Kaspar, Fabienne Wittling, Olga Hartwig, Jannic Federspiel, India Findji, Uwe Walldorf

    Background: The homeobox genehomeobrain(hbn) is located in the 57B region together with two other homeobox genes,Drosophila Retinal homeobox(DRx) andorthopedia(otp). All three genes encode transcription factors with important functions in brain development.Hbnmutants are embryonic lethal and characterized by a reduction in the anterior protocerebrum, including the mushroom bodies, and a loss of the supraoesophageal brain commissure.Results: In this study we conducted a detailed expression analysis of Hbn in later developmental stages. In the larval brain, Hbn is expressed in all type II lineages and the optic lobes, including the medulla and lobula plug. The gene is expressed in the cortex of the medulla and the lobula rim in the adult brain. We generated a new hbnKOGal4enhancer trap strain by reintegrating Gal4 in thehbnlocus through gene targeting, which reflects the completehbnexpression during development. Eight different enhancer-Gal4 strains covering 12 kb upstream ofhbn, the two large introns and 5 kb downstream of the gene, were established andhbnexpression was investigated. We characterized several enhancers that drive expression in specific areas of the brain throughout development, from embryo to the adulthood. Finally, we generated deletions of four of these enhancer regions through gene targeting and analysed their effects on the expression and function ofhbn.Conclusion: The complex expression of Hbn in the developing brain is regulated by several specific enhancers within thehbnlocus. Each enhancer fragment driveshbnexpression in several specific cell lineages, and with largely overlapping patterns, suggesting the presence of shadow enhancers and enhancer redundancy. Specific enhancer deletion strains generated by gene targeting display developmental defects in the brain. This analysis opens an avenue for a deeper analysis ofhbnregulatory elements in the future.


  • Drug delivery to the inflamed intestinal mucosa – targeting technologies and human cell culture models for better therapies of IBD

    by Olga Hartwig, Maryam A. Shetab Boushehri, Karim S. Shalaby, Brigitta Loretz, Alf Lamprecht, Claus-Michael Lehr